Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults

Journal of Infectious Diseases

Volumn 206, Issue 3, 2012, Pages 421-430

  Flynn, Patricia M ^a   Nachman, Sharon ^b   Muresan, Petronella ^c   Fenton, Terence ^c   Spector, Stephen A ^d,e   Cunningham, Coleen K ^f   Pass, Robert ^g   Yogev, Ram ^h   Burchett, Sandra ⁱ   Heckman, Barbara ^j   Bloom, Anthony ^j   Utech, L Jill ^a   Anthony, Patricia ^k   Petzold, Elizabeth ^l   Levy, Wende ^l   Siberry, George K ^m   Ebiasah, Ruth ⁿ   Miller, Judi ⁿ   Handelsman, Edward ⁿ   Weinberg, Adriana ^o  

^a Jude Children's Research Hospital   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^m EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FACIAL NERVE PARALYSIS; FEMALE; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HEMAGGLUTINATION INHIBITION TEST; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; INJECTION SITE REACTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEROLOGY; SEROPROTECTION; SERORESPONSE; SIDE EFFECT; VACCINATION REACTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REACTIVATION; VOMITING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; PANDEMICS; VIRAL VACCINES; YOUNG ADULT;

EID: 84863915909     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis360     Document Type: Article

References (50)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15.
2. Peiris JS, Poon LL, Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009; 45:169-73.
3. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol 2009; 45:174-8.
4. World Health Organization. Global Alert and Response: Situation Updates (Pandemic) H1N1 2009. http://www.who.int/csr/disease/swineflu/updates/en/index. html. Accessed May 29, 2012.
5. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19.
6. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001; 32:1784-91.
7. Madhi SA, Ramasamy N, Bessellar TG, Saloojee H, Klugman KP. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002; 21:291-7.
8. Mendoza Sanchez MC, Ruiz-Contreras J, Vivanco JL, et al. Respiratory virus infections in children with cancer or HIV infection. J Pediatr Hematol Oncol 2006; 28:154-9.
9. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469-76.
10. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83.
11. King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-8.
12. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-7.
13. Lyall EG, Charlett A, Watkins P, Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child 1997; 76:215-8.
14. Jackson CR, Vavro CL, Valentine ME, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 1997; 16:200-4.
15. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:206-11.
16. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-96.
17. Ennis FA, Mayner RE, Barry DW, et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 1977; 136(Suppl):S397-406.
18. Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 1972; 125:656-64.
19. Ruben FL, Potter CW, Stuart-Harris CH. Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine. Arch Virol 1975; 47:157-66.
20. Palache AM, Beyer WE, Sprenger MJ, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11:3-9.
21. Keitel WA, Couch RB, Cate TR, et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994; 32:2468-73.
22. Keitel WA, Cate TR, Atmar RL, et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 1996; 3:507-10.
23. Keitel WA, Atmar RL, Nino D, Cate TR, Couch RB. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis 2008; 198:1016-8.
24. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
25. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
26. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18.
27. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010; 362:370-2.
28. Plennevaux E, Blatter M, Cornish MJ, et al. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine 2011; 29:1569-75.
29. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.
30. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8.
31. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66.
32. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23.
33. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37-46.
34. Lu CY, Shao PL, Chang LY, et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 2010; 28:5864-70.
35. Oh CE, Lee J, Kang JH, et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: A prospective, open-label, multi-center trial
36. Weinberg A, Song LY, Walker R, et al. Anti-inflenza serum and mucosal antibody responses after administration of live, attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010; 55:189-96.
37. Crum-Cianflone NF, Iverson E, Defang G, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011; 29:3183-91.
38. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46.
39. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-92.
40. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52: 122-7.
41. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIVinfected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:e16496.
42. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56.
43. Esposito S, Tagliaferri L, Daleno C, et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011; 29:1677-82.
44. Viganò A, Giacomet V, Pariani E, et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin Vaccine Immunol 2011; 18:1503-9.
45. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193:302-11.
46. Tarragó D, Casal J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12:165-70.
47. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248-55.
48. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT, the VAERS Working Group. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Pharmacoepidemiol Drug Saf 2004; 13:505-10.
49. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
50. Kok J, Tudo K, Blyth CC, Foo H, Hueston L, Dwyer DE. Pandemic (H1N1) 2009 influenza virus seroconversion rates in HIV-infected individuals. J Acquir Immune Defic Syndr 2011; 56:91-4.